Browse studies

Find your next paid study

8 recruiting studies matching your filters

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pemb…

Advanced Non-Small Cell Lung CancerNon-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lung+3 more

A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSC…

Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+1 more

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT07154290

Phase 1

A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune syst…

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part SarcomaLocally Advanced Non Small Cell Lung Cancer+7 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06066138

Phase 1

Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging

The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconiu…

Lung CancerNon Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06863233

Phase 1

A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

Tumor SkinMetastatic MelanomaMelanoma+4 more

Estimated

~$10 – $8,750

Obsidian Therapeutics, Inc.NCT06060613

Phase 2

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung ca…

Metastatic Non Small Cell Lung Cancer

Estimated

~$10 – $8,750

Iovance Biotherapeutics, Inc.NCT04614103

Phase 1

Phase I Clinical Trial of Autologous Folate Receptor-Alpha Redirected T Cells in Patients With FRa+ Cancers

This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells…

Metastatic Non Small Cell Lung CancerRecurrent Lung Non-Small Cell Carcinoma

Estimated

~$10 – $6,250

University of PennsylvaniaNCT07116057

Phase 2

Phase 2 Study to Evaluate Reduced Dose Chemotherapy in Combination With Anti-PD-1 Therapy as First Line Treatment in Vulnerable or Older Adults (Vulnerable or Age ≥70) With Advanced PD-L1 TPS <50% Non-small Cell Lung Cancer

Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patien…

Non-Small Cell Lung CancerNSCLCAdvanced Non-Small Cell Lung Cancer+1 more

Estimated

~$10 – $6,250

Virginia Commonwealth UniversityNCT06731413